Antoni J. Duleba
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Antoni J. Duleba has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
Beata Banaszewska
Department of Laboratory Diagnostics, Poznan University of Medical Sciences, Poznan, Poland 6
6 shared publicationsLeszek Pawelczyk
Department of Gynecological Endocrinology and Infertility Treatment, Department od Diagnostics and Treatment of Infertility, Poznan University of Medical Sciences, Poznan, Poland 1
5 shared publicationsIsrael Ortega
IVI-Madrid, Madrid, Spain
4 shared publicationsMartyna Siakowska
Division of Infertility and Reproductive Endocrinology, Department of Gynecology, Obstetrics and Gynecological Oncology, Poznan University of Medical Sciences, Poznań, Poland
4 shared publicationsAnna Sokalska
University of Pennsylvania
3 shared publicationsBarbara Zwozdziak
Department of Medical Microbiology, Poznan University of Medical Sciences, Poznań, Poland
3 shared publications
Latest Publications
- Open Access
- 17 April 2026
- Published by Bioscientifica in Endocrine Connections
- Vol. 15 (5)
Metformin improves endotoxemia and alters folliculogenesis in women with polycystic ovary syndrome
Polycystic ovary syndrome (PCOS) is associated with excessive ovarian androgen production, an increased number of ovarian follicles and a wide range of other endocrine and metabolic derangements, including endotoxemia. Metformin is often used in the treatment of PCOS, especially to improve glucose metabolism. This study evaluated the effects of metformin on endotoxemia, folliculogenesis and endocrine profiles. In a prospective trial, women with PCOS received metformin (500 mg t.i.d.) for three months and underwent baseline and post-treatment evaluations of their endocrine and metabolic profiles as well as detailed ultrasonographic evaluations of ovaries. Metformin treatment was associated with reduced lipopolysaccharides (LPSs) by 19% (P < 0.0001) and LPS-binding protein (LPB) by 26% (P < 0.0001). In parallel, the number of small antral follicles (<6 mm) declined by 8% (P = 0.005), total testosterone decreased by 13% (P = 0.0003), ovarian testosterone production in response to hCG declined by 73% (P = 0.03), and fasting insulin decreased by 19% (P = 0.02). The reduction in testosterone following treatment with metformin may be due to a combination of multiple effects of metformin, including improvement in endotoxemia, reduction in folliculogenesis and decreased insulin. Clinical trial registration number: NCT03489668
- 17 April 2026
- Published by Bioscientifica in Endocrine Connections
- Vol. 15 (5)
Open AccessMetformin improves endotoxemia and alters folliculogenesis in women with polycystic ovary syndrome
Polycystic ovary syndrome (PCOS) is associated with excessive ovarian androgen production, an increased number of ovarian follicles and a wide range of other endocrine and metabolic derangements, including endotoxemia. Metformin is often used in the treatment of PCOS, especially to improve glucose metabolism. This study evaluated the effects of metformin on endotoxemia, folliculogenesis and endocrine profiles. In a prospective trial, women with PCOS received metformin (500 mg t.i.d.) for three months and underwent baseline and post-treatment evaluations of their endocrine and metabolic profiles as well as detailed ultrasonographic evaluations of ovaries. Metformin treatment was associated with reduced lipopolysaccharides (LPSs) by 19% (P < 0.0001) and LPS-binding protein (LPB) by 26% (P < 0.0001). In parallel, the number of small antral follicles (<6 mm) declined by 8% (P = 0.005), total testosterone decreased by 13% (P = 0.0003), ovarian testosterone production in response to hCG declined by 73% (P = 0.03), and fasting insulin decreased by 19% (P = 0.02). The reduction in testosterone following treatment with metformin may be due to a combination of multiple effects of metformin, including improvement in endotoxemia, reduction in folliculogenesis and decreased insulin. Clinical trial registration number: NCT03489668
- Open Access
- 5 December 2024
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 311 (2) , 499-506
Six-month randomized, placebo controlled trial of synbiotic supplementation in women with polycystic ovary syndrome undergoing lifestyle modifications
Purpose: To determine whether long-term administration of synbiotics affects clinical, endocrine and metabolic aspects of polycystic ovary syndrome (PCOS) in overweight and obese subjects undergoing intensive lifestyle modifications. Methods: During six-month trial, all subjects underwent intensive lifestyle modifications (diet and exercise). The subjects were randomized (1:1) to receive synbiotic supplementation (Synbiotic Group) or placebo (Placebo Group). Results: Subjects in the Placebo Group and the Synbiotic Group experienced significant reduction of BMI (− 8% and − 11%, respectively; both at P < 0.0001) and body fat percentage (− 11% and − 14%, respectively; both at P < 0.0001). These effects were statistically comparable for both groups. Total testosterone was not significantly changed in the Placebo Group (− 5%, P = 0.41) while it greatly declined in the Synbiotic Group (− 40%; P < 0.0001); the difference between these groups was significant (P = 0.0002). Synbiotic supplementation was superior to placebo in reducing LH (− 21%; P = 0.047), total cholesterol (− 6%; P = 0.002), low-density lipoprotein cholesterol (− 6%; P = 0.044), triglycerides (− 29%; P = 0.049), LPS (− 23%; P = 0.001) and LPS-binding protein (− 21%; P = 0.001). Conclusions: Synbiotic supplementation led to a marked improvement of several key clinical and laboratory aspects of PCOS including an improvement of hyperandrogenism, lipid profile, and markers of endotoxemia. Trial registration: Clinical Trial Registration Number: NCT03325023 (URL, clinicaltrials.gov; date of registration 10/26/2017).
- 5 December 2024
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 311 (2) , 499-506
Open AccessSix-month randomized, placebo controlled trial of synbiotic supplementation in women with polycystic ovary syndrome undergoing lifestyle modifications
Purpose: To determine whether long-term administration of synbiotics affects clinical, endocrine and metabolic aspects of polycystic ovary syndrome (PCOS) in overweight and obese subjects undergoing intensive lifestyle modifications. Methods: During six-month trial, all subjects underwent intensive lifestyle modifications (diet and exercise). The subjects were randomized (1:1) to receive synbiotic supplementation (Synbiotic Group) or placebo (Placebo Group). Results: Subjects in the Placebo Group and the Synbiotic Group experienced significant reduction of BMI (− 8% and − 11%, respectively; both at P < 0.0001) and body fat percentage (− 11% and − 14%, respectively; both at P < 0.0001). These effects were statistically comparable for both groups. Total testosterone was not significantly changed in the Placebo Group (− 5%, P = 0.41) while it greatly declined in the Synbiotic Group (− 40%; P < 0.0001); the difference between these groups was significant (P = 0.0002). Synbiotic supplementation was superior to placebo in reducing LH (− 21%; P = 0.047), total cholesterol (− 6%; P = 0.002), low-density lipoprotein cholesterol (− 6%; P = 0.044), triglycerides (− 29%; P = 0.049), LPS (− 23%; P = 0.001) and LPS-binding protein (− 21%; P = 0.001). Conclusions: Synbiotic supplementation led to a marked improvement of several key clinical and laboratory aspects of PCOS including an improvement of hyperandrogenism, lipid profile, and markers of endotoxemia. Trial registration: Clinical Trial Registration Number: NCT03325023 (URL, clinicaltrials.gov; date of registration 10/26/2017).
- Open Access
- 1 May 2023
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 210 (Supplement) , 79.15
Open Chromatin: The Guide to Inflammatory Mediators in PCOS
Inflammation comorbid with insulin resistance and metabolic dysfunction are major manifestations of Polycystic Ovary Syndrome (PCOS). However, the type of inflammation associated with POCS and its effect remains uncharacterized making it important to identify inflammatory mediators that contribute to PCOS-related metabolic dysfunction. Our data from a mouse model of PCOS shows increased secretion of proinflammatory cytokines from Th17 cells. Th17 inflammation is associated with metabolic dysfunction in type 2 diabetes. Therefore, we hypothesize that Th17 cells predominate PCOS-specific inflammation. We will test this hypothesis using peripheral blood mononuclear cells (PBMCs) collected from a prospective cohort of 20 fully clinically characterized Polish women: 15 with PCOS and 5 without. Combinations of cytokines and transcription factors, specific to different immune cell types, will have enhanced access to inflammation-related loci promoting transcription. We have used assay for transposase-accessible chromatin with sequencing (ATAC-Seq) of nuclei extracted from the PBMCs of our cohort to test whether chromatin loci important for Th17 cells are accessible as reflected by regions of open chromatin in immune cells of patients with PCOS. We expect our ATAC-seq data to distinguish women with PCOS from control by an open chromatin signature that represents distinct cytokine profiles and Th17 specific transcription factor binding sites. This is the first step to generating a multivariable map of inflammation in this metabolic disease, with the long-term objective being the development of targeted anti-inflammatory therapeutics for PCOS and comorbid insulin resistance. NIH grant#3TR00HD09833004S1 from NICHD NIH grant#5TR00HD09833004 from NICHD
- 1 May 2023
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 210 (Supplement) , 79.15
Open AccessOpen Chromatin: The Guide to Inflammatory Mediators in PCOS
Inflammation comorbid with insulin resistance and metabolic dysfunction are major manifestations of Polycystic Ovary Syndrome (PCOS). However, the type of inflammation associated with POCS and its effect remains uncharacterized making it important to identify inflammatory mediators that contribute to PCOS-related metabolic dysfunction. Our data from a mouse model of PCOS shows increased secretion of proinflammatory cytokines from Th17 cells. Th17 inflammation is associated with metabolic dysfunction in type 2 diabetes. Therefore, we hypothesize that Th17 cells predominate PCOS-specific inflammation. We will test this hypothesis using peripheral blood mononuclear cells (PBMCs) collected from a prospective cohort of 20 fully clinically characterized Polish women: 15 with PCOS and 5 without. Combinations of cytokines and transcription factors, specific to different immune cell types, will have enhanced access to inflammation-related loci promoting transcription. We have used assay for transposase-accessible chromatin with sequencing (ATAC-Seq) of nuclei extracted from the PBMCs of our cohort to test whether chromatin loci important for Th17 cells are accessible as reflected by regions of open chromatin in immune cells of patients with PCOS. We expect our ATAC-seq data to distinguish women with PCOS from control by an open chromatin signature that represents distinct cytokine profiles and Th17 specific transcription factor binding sites. This is the first step to generating a multivariable map of inflammation in this metabolic disease, with the long-term objective being the development of targeted anti-inflammatory therapeutics for PCOS and comorbid insulin resistance. NIH grant#3TR00HD09833004S1 from NICHD NIH grant#5TR00HD09833004 from NICHD
- Open Access
- 13 August 2022
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 6 (10) , bvac128
Ibuprofen Reduces Testosterone Level in Women With Polycystic Ovary Syndrome
Context Hyperandrogenism is a central feature of polycystic ovary syndrome (PCOS). In vitro studies have demonstrated that inflammatory stimuli promote whereas ibuprofen inhibits androgen production by ovarian theca-interstitial cells. Objective This work aimed to determine the effects of nonselective inhibitor of cyclooxygenases COX-1 and COX-2 on testosterone levels. Methods A prospective pilot study took place in an academic hospital of women with PCOS defined according to Rotterdam criteria (N = 20). Evaluations were taken at baseline and after 3 weeks of ibuprofen administration (400 mg twice a day or 400 mg 3 times a day, respectively, in women with weight < and ≥ 70 kg). The main outcome measure was total serum testosterone. Results Ibuprofen administration was associated with a decline of total testosterone from 0.75 ± 0.06 ng/mL to 0.59 ± 0.05 ng/mL (P = .008). There was no statistically significant change in the levels of other relevant hormones including dehydroepiandrosterone sulfate, gonadotropins, and insulin. Multiple regression analysis identified the greatest decline of testosterone was independently predicted by baseline testosterone level (P = .004) and by baseline insulin sensitivity index (P = .03). Conclusion Nonselective inhibition of COX-1 and COX-2 leads to selective reduction of testosterone consistent with direct inhibitory effect on ovarian steroidogenesis.
- 13 August 2022
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 6 (10) , bvac128
Open AccessIbuprofen Reduces Testosterone Level in Women With Polycystic Ovary Syndrome
Context Hyperandrogenism is a central feature of polycystic ovary syndrome (PCOS). In vitro studies have demonstrated that inflammatory stimuli promote whereas ibuprofen inhibits androgen production by ovarian theca-interstitial cells. Objective This work aimed to determine the effects of nonselective inhibitor of cyclooxygenases COX-1 and COX-2 on testosterone levels. Methods A prospective pilot study took place in an academic hospital of women with PCOS defined according to Rotterdam criteria (N = 20). Evaluations were taken at baseline and after 3 weeks of ibuprofen administration (400 mg twice a day or 400 mg 3 times a day, respectively, in women with weight < and ≥ 70 kg). The main outcome measure was total serum testosterone. Results Ibuprofen administration was associated with a decline of total testosterone from 0.75 ± 0.06 ng/mL to 0.59 ± 0.05 ng/mL (P = .008). There was no statistically significant change in the levels of other relevant hormones including dehydroepiandrosterone sulfate, gonadotropins, and insulin. Multiple regression analysis identified the greatest decline of testosterone was independently predicted by baseline testosterone level (P = .004) and by baseline insulin sensitivity index (P = .03). Conclusion Nonselective inhibition of COX-1 and COX-2 leads to selective reduction of testosterone consistent with direct inhibitory effect on ovarian steroidogenesis.
- 14 April 2022
- Published by Springer Nature
- p. 255-277
Role of Statins and Resveratrol in PCOS Management
- 14 April 2022
- Published by Springer Nature
- p. 255-277
Role of Statins and Resveratrol in PCOS Management
- 29 May 2021
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 106 (9) , 2566-2573
Effects of Synbiotic Supplementation and Lifestyle Modifications on Women With Polycystic Ovary Syndrome
Context: Polycystic ovary syndrome (PCOS) is the most common endocrinopathy affecting women of reproductive age. Objective: This study was designed to evaluate effects of lifestyle modifications and synbiotic supplementation on PCOS. Design: A randomized (1:1) double-blind, placebo-controlled trial. Setting: Academic hospital. Patients or Other Participants: Overweight and obese women with PCOS were identified according to the Rotterdam criteria. Evaluations were performed at baseline and repeated after 3 months of treatment. Intervention: Lifestyle modifications in combination with synbiotic supplementation or placebo. Main Outcome Measures: Change in body mass index (BMI) and testosterone level. Results: In the placebo group, a 5% decrease in BMI was accompanied by significant decreases of the waist, hip, and thigh circumferences. The synbiotic group experienced an 8% decrease in BMI, which was significantly greater than that in the control group (P = 0.03) and was accompanied by decreases in the waist, hip, and thigh circumferences. Testosterone did not decrease significantly in the placebo group (decrease of 6%), whereas in the synbiotic group it decreased by 32% (P < 0.0001). The decrease of testosterone was significantly greater in the synbiotic group than in the placebo group (P = 0.016). Conclusions: Synbiotic supplementation potentiated effects of lifestyle modifications on weight loss and led to significant reduction of serum testosterone.
- 29 May 2021
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 106 (9) , 2566-2573
Effects of Synbiotic Supplementation and Lifestyle Modifications on Women With Polycystic Ovary Syndrome
Context: Polycystic ovary syndrome (PCOS) is the most common endocrinopathy affecting women of reproductive age. Objective: This study was designed to evaluate effects of lifestyle modifications and synbiotic supplementation on PCOS. Design: A randomized (1:1) double-blind, placebo-controlled trial. Setting: Academic hospital. Patients or Other Participants: Overweight and obese women with PCOS were identified according to the Rotterdam criteria. Evaluations were performed at baseline and repeated after 3 months of treatment. Intervention: Lifestyle modifications in combination with synbiotic supplementation or placebo. Main Outcome Measures: Change in body mass index (BMI) and testosterone level. Results: In the placebo group, a 5% decrease in BMI was accompanied by significant decreases of the waist, hip, and thigh circumferences. The synbiotic group experienced an 8% decrease in BMI, which was significantly greater than that in the control group (P = 0.03) and was accompanied by decreases in the waist, hip, and thigh circumferences. Testosterone did not decrease significantly in the placebo group (decrease of 6%), whereas in the synbiotic group it decreased by 32% (P < 0.0001). The decrease of testosterone was significantly greater in the synbiotic group than in the placebo group (P = 0.016). Conclusions: Synbiotic supplementation potentiated effects of lifestyle modifications on weight loss and led to significant reduction of serum testosterone.
- 1 September 2020
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 35 (10) , 2303-2311
Elevation of markers of endotoxemia in women with polycystic ovary syndrome
Is polycystic ovary syndrome (PCOS) associated with an elevation of markers of endotoxemia? In women with PCOS serum levels of lipopolysaccharides (LPS), the LPS to high-density lipoprotein (HDL) ratio and LPS-binding protein (LBP) are significantly greater than those of normal control subjects. Mononuclear cells from women with PCOS respond excessively to LPS by releasing pro-inflammatory cytokines. In rat ovarian theca-interstitial cell cultures LPS stimulates androgen production. Cross-sectional study comparing markers of endotoxemia in women with PCOS (n = 62), healthy ovulatory women with polycystic ovary morphology (PCOM, n = 39) and a control group of healthy ovulatory women without PCOM [normal (NL), n = 43]. LPS was measured using a chromogenic assay. LBP was measured by ELISA. Total cholesterol and lipids were measured using a homogeneous enzyme colorimetric method. Androgens, gonadotrophins, prolactin, insulin, high-sensitivity C-reactive protein (hs-CRP) and sex hormone-binding globulin were determined by electrochemiluminescence assays. Glucose was measured using an enzymatic reference method with hexokinase. Women with PCOS, when compared with NL subjects, had a significantly higher mean LPS (P = 0.045), LPS/HDL ratio (P = 0.007) and LBP (P = 0.01). Women with PCOM had intermediate levels of markers of endotoxemia. Comparison among all groups revealed that markers of endotoxemia correlated positively with testosterone level, ovarian volume, number of antral follicles and hirsutism score, but negatively with the number of spontaneous menses per year. In multiple regression analysis, all measures of endotoxemia correlated independently and positively with hs-CRP and with ovarian volume. This cross-sectional study reveals that markers of endotoxemia are associated with several clinical features observed in women with PCOS. However, responsible mechanisms and causation remain unknown. Steroid quantification was carried out by electrochemiluminescence assays and not by the current gold standard: liquid chromatography-mass spectrometry. Hence, the relationship of endotoxemia with features of PCOS and the extent to which endotoxemia contributes to reproductive and metabolic dysfunction warrants further investigation. This study reveals the novel observation that markers of endotoxemia are elevated in young and otherwise healthy women with PCOS without significant metabolic dysfunction. Moreover, the association of clinical and endocrine markers of PCOS with those of endotoxemia may represent a pathophysiologic link to reproductive dysfunction as well as metabolic and long-term cardiovascular risks associated with this disorder. Intramural funding from Poznan University of Medical Sciences. The authors have no conflicts of interest to declare. N/A
- 1 September 2020
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 35 (10) , 2303-2311
Elevation of markers of endotoxemia in women with polycystic ovary syndrome
Is polycystic ovary syndrome (PCOS) associated with an elevation of markers of endotoxemia? In women with PCOS serum levels of lipopolysaccharides (LPS), the LPS to high-density lipoprotein (HDL) ratio and LPS-binding protein (LBP) are significantly greater than those of normal control subjects. Mononuclear cells from women with PCOS respond excessively to LPS by releasing pro-inflammatory cytokines. In rat ovarian theca-interstitial cell cultures LPS stimulates androgen production. Cross-sectional study comparing markers of endotoxemia in women with PCOS (n = 62), healthy ovulatory women with polycystic ovary morphology (PCOM, n = 39) and a control group of healthy ovulatory women without PCOM [normal (NL), n = 43]. LPS was measured using a chromogenic assay. LBP was measured by ELISA. Total cholesterol and lipids were measured using a homogeneous enzyme colorimetric method. Androgens, gonadotrophins, prolactin, insulin, high-sensitivity C-reactive protein (hs-CRP) and sex hormone-binding globulin were determined by electrochemiluminescence assays. Glucose was measured using an enzymatic reference method with hexokinase. Women with PCOS, when compared with NL subjects, had a significantly higher mean LPS (P = 0.045), LPS/HDL ratio (P = 0.007) and LBP (P = 0.01). Women with PCOM had intermediate levels of markers of endotoxemia. Comparison among all groups revealed that markers of endotoxemia correlated positively with testosterone level, ovarian volume, number of antral follicles and hirsutism score, but negatively with the number of spontaneous menses per year. In multiple regression analysis, all measures of endotoxemia correlated independently and positively with hs-CRP and with ovarian volume. This cross-sectional study reveals that markers of endotoxemia are associated with several clinical features observed in women with PCOS. However, responsible mechanisms and causation remain unknown. Steroid quantification was carried out by electrochemiluminescence assays and not by the current gold standard: liquid chromatography-mass spectrometry. Hence, the relationship of endotoxemia with features of PCOS and the extent to which endotoxemia contributes to reproductive and metabolic dysfunction warrants further investigation. This study reveals the novel observation that markers of endotoxemia are elevated in young and otherwise healthy women with PCOS without significant metabolic dysfunction. Moreover, the association of clinical and endocrine markers of PCOS with those of endotoxemia may represent a pathophysiologic link to reproductive dysfunction as well as metabolic and long-term cardiovascular risks associated with this disorder. Intramural funding from Poznan University of Medical Sciences. The authors have no conflicts of interest to declare. N/A
- 1 April 2020
- Published by Springer Nature in Reproductive Sciences
- Vol. 27 (4) , 1002-1007
Androgens Modulate Rat Granulosa Cell Steroidogenesis
Paracrine interactions between ovarian theca-interstitial cells (TICs) and granulosa cells (GCs) play an important role in the regulation of follicular steroidogenesis. Androgens serve as substrates for aromatization as well as affect GC function. This study evaluated the effects of co-culture of GC with TICs and the role of testosterone (T) and 5-alpha-dihydrotestosterone (DHT), and estradiol (E2) in modulation of GC expression of genes involved in the production of progesterone: 3 beta-hydroxysteroid dehydrogenase/Delta(5-4) isomerase (Hsd3b) and cholesterol side-chain cleavage (Cyp11). GCs obtained from immature Sprague-Dawley rats and were cultured in chemically defined media without or with TICs, DHT, or T. Hsd3b and Cyp11 transcripts were analyzed by qt-PCR. Co-culture of GCs with TICs stimulated Hsd3b and CYP11 expression in GCs. DHT and T induced a concentration-dependent upregulation of Hsd3b and CYP11 expression, as well as increased progesterone concentrations in spent media. E2 also increased expression of Hsd3b, and Cyp11. Effects of androgens were abrogated in the presence of an anti-androgen bicalutamide and the antiestrogen ICI 182780 (ICI). In conclusion, present findings demonstrate that androgens upregulate production of progesterone in GCs; these effects are likely due to a combination of direct action on androgen receptors and effects mediated by estrogen receptors.
- 1 April 2020
- Published by Springer Nature in Reproductive Sciences
- Vol. 27 (4) , 1002-1007
Androgens Modulate Rat Granulosa Cell Steroidogenesis
Paracrine interactions between ovarian theca-interstitial cells (TICs) and granulosa cells (GCs) play an important role in the regulation of follicular steroidogenesis. Androgens serve as substrates for aromatization as well as affect GC function. This study evaluated the effects of co-culture of GC with TICs and the role of testosterone (T) and 5-alpha-dihydrotestosterone (DHT), and estradiol (E2) in modulation of GC expression of genes involved in the production of progesterone: 3 beta-hydroxysteroid dehydrogenase/Delta(5-4) isomerase (Hsd3b) and cholesterol side-chain cleavage (Cyp11). GCs obtained from immature Sprague-Dawley rats and were cultured in chemically defined media without or with TICs, DHT, or T. Hsd3b and Cyp11 transcripts were analyzed by qt-PCR. Co-culture of GCs with TICs stimulated Hsd3b and CYP11 expression in GCs. DHT and T induced a concentration-dependent upregulation of Hsd3b and CYP11 expression, as well as increased progesterone concentrations in spent media. E2 also increased expression of Hsd3b, and Cyp11. Effects of androgens were abrogated in the presence of an anti-androgen bicalutamide and the antiestrogen ICI 182780 (ICI). In conclusion, present findings demonstrate that androgens upregulate production of progesterone in GCs; these effects are likely due to a combination of direct action on androgen receptors and effects mediated by estrogen receptors.
- 1 January 2020
- Published by Springer Nature in Reproductive Sciences
- Vol. 27 (1) , 432-442
Disparate Relationship of Sexual Satisfaction, Self-Esteem, Anxiety, and Depression with Endocrine Profiles of Women With or Without PCOS
Women with polycystic ovary syndrome (PCOS) are at increased risk of psychological distress including anxiety and depressive symptoms. However, less is known about sexual satisfaction and self-esteem as well as the relationship of these aspects of psychological function with clinical and hormonal profiles associated with PCOS. This cross-sectional study compared women with PCOS (N = 96) and healthy controls (N = 47). This study assessed sexual function (primary outcome), self-esteem, anxiety, and depression as well as evaluation of clinical, endocrine, and metabolic parameters. Overall, sexual satisfaction scores were comparable among women with and without PCOS. However, psychosexual function of women with PCOS exhibited distinguishing characteristics. The unconscious aspect of sexuality: frequency of erotic dreams, significantly correlated with free testosterone (ρ = 0.24, P = 0.03) and DHEAS (ρ = 0.31, P = 0.004) only in the PCOS group. In contrast, in women with PCOS, the frequency of masturbation did not correlate with endocrine profiles, but correlated with trait anxiety (ρ = 0.21, P = 0.049) and depression (ρ = 0.21, P = 0.05). Only one aspect of self-esteem (body appearance) was reduced in the PCOS group (P = 0.02) and was related to BMI and androgen. Women with PCOS had greater state anxiety (P = 0.02) and depression (P < 0.001); these scores correlated with BMI. However, anxiety and depression correlated with testosterone only in women without PCOS. The above findings indicate that PCOS is associated with a broad range of alterations of psychological function including psychosexual aspects; these alterations are in complex relationship with BMI and androgen levels.
- 1 January 2020
- Published by Springer Nature in Reproductive Sciences
- Vol. 27 (1) , 432-442
Disparate Relationship of Sexual Satisfaction, Self-Esteem, Anxiety, and Depression with Endocrine Profiles of Women With or Without PCOS
Women with polycystic ovary syndrome (PCOS) are at increased risk of psychological distress including anxiety and depressive symptoms. However, less is known about sexual satisfaction and self-esteem as well as the relationship of these aspects of psychological function with clinical and hormonal profiles associated with PCOS. This cross-sectional study compared women with PCOS (N = 96) and healthy controls (N = 47). This study assessed sexual function (primary outcome), self-esteem, anxiety, and depression as well as evaluation of clinical, endocrine, and metabolic parameters. Overall, sexual satisfaction scores were comparable among women with and without PCOS. However, psychosexual function of women with PCOS exhibited distinguishing characteristics. The unconscious aspect of sexuality: frequency of erotic dreams, significantly correlated with free testosterone (ρ = 0.24, P = 0.03) and DHEAS (ρ = 0.31, P = 0.004) only in the PCOS group. In contrast, in women with PCOS, the frequency of masturbation did not correlate with endocrine profiles, but correlated with trait anxiety (ρ = 0.21, P = 0.049) and depression (ρ = 0.21, P = 0.05). Only one aspect of self-esteem (body appearance) was reduced in the PCOS group (P = 0.02) and was related to BMI and androgen. Women with PCOS had greater state anxiety (P = 0.02) and depression (P < 0.001); these scores correlated with BMI. However, anxiety and depression correlated with testosterone only in women without PCOS. The above findings indicate that PCOS is associated with a broad range of alterations of psychological function including psychosexual aspects; these alterations are in complex relationship with BMI and androgen levels.
- 9 December 2019
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 36 (6) , 496-500
Relationship between adipocytokines and angiotensin converting enzyme gene insertion/deletion polymorphism in lean women with and without polycystic ovary syndrome
This study was designed to investigate the relationship between the levels of select adipocytokines (adiponectin, visfatin and apelin) and angiotensin in converting enzyme (ACE) gene insertion/deletion (ID) polymorphism in lean women with and without polycystic ovary syndrome (PCOS). The PCOS group (N = 94) was identified according to the Rotterdam criteria. The Control group (N = 68) included age- and body mass index (BMI)-matched healthy volunteers. Serum levels of adipocytokines were measured using enzyme immunoassays (EIA) and ACE genes were evaluated by polymerase chain reaction (PCR). The PCOS group, when compared to the Control group had lower adiponectin (p < .001) but higher visfatin (p < .001) and apelin (p = .003). There was no significant correlation of the levels of these adipocytokines with BMI, fasting glucose, fasting insulin or Homeostasis Model Assessment-Insulin Resistance (HOMA-IR). The PCOS and the Control groups also differed with regard to the ACE ID genotype distribution (p < .001). The ID, DD, and II genotype frequencies were, respectively, 34, 57 and 9% in the PCOS group and 49, 22 and 29% in the Control group. When stratified according to individual ID genotypes, the levels of adipocytokines in the PCOS and the Control groups remained significantly different. There was no statistically significant relationship between the levels of adipocytokines and ACE ID genotypes.
- 9 December 2019
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 36 (6) , 496-500
Relationship between adipocytokines and angiotensin converting enzyme gene insertion/deletion polymorphism in lean women with and without polycystic ovary syndrome
This study was designed to investigate the relationship between the levels of select adipocytokines (adiponectin, visfatin and apelin) and angiotensin in converting enzyme (ACE) gene insertion/deletion (ID) polymorphism in lean women with and without polycystic ovary syndrome (PCOS). The PCOS group (N = 94) was identified according to the Rotterdam criteria. The Control group (N = 68) included age- and body mass index (BMI)-matched healthy volunteers. Serum levels of adipocytokines were measured using enzyme immunoassays (EIA) and ACE genes were evaluated by polymerase chain reaction (PCR). The PCOS group, when compared to the Control group had lower adiponectin (p < .001) but higher visfatin (p < .001) and apelin (p = .003). There was no significant correlation of the levels of these adipocytokines with BMI, fasting glucose, fasting insulin or Homeostasis Model Assessment-Insulin Resistance (HOMA-IR). The PCOS and the Control groups also differed with regard to the ACE ID genotype distribution (p < .001). The ID, DD, and II genotype frequencies were, respectively, 34, 57 and 9% in the PCOS group and 49, 22 and 29% in the Control group. When stratified according to individual ID genotypes, the levels of adipocytokines in the PCOS and the Control groups remained significantly different. There was no statistically significant relationship between the levels of adipocytokines and ACE ID genotypes.